Core Viewpoint - The company has approved an employee stock ownership plan (ESOP) aimed at enhancing employee engagement and aligning their interests with shareholders through stock ownership [1][2]. Group 1: Employee Stock Ownership Plan Approval - The company held a board meeting on December 12, 2024, and a shareholder meeting on December 30, 2024, to approve the ESOP and related management measures [1]. - The board authorized the management to handle matters related to the ESOP implementation [1]. Group 2: Stock Buyback Details - The company plans to repurchase between 7 million and 13.5 million shares of its A-shares, with a maximum buyback price of 9.80 yuan per share, totaling up to 132.3 million yuan [2]. - The actual buyback completed was 10,396,000 shares, costing approximately 69.99 million yuan [2]. Group 3: Fundraising and Subscription Details - The ESOP aims to raise a total of up to 46.68 million yuan, with a subscription price of 4.49 yuan per share, allowing for the purchase of up to 10.396 million shares [4]. - The actual funds raised amounted to 31.74 million yuan, with 29 employees participating in the subscription [4]. Group 4: Share Transfer and Accounting - As of February 12, 2026, 7,070,000 shares were transferred to the ESOP account, representing 1.393% of the company's total share capital [5]. - The company will follow accounting standards for share-based payments to assess the impact of the ESOP on its financial results [7]. Group 5: Independence and Governance - The first major shareholder did not participate in the ESOP, ensuring no conflict of interest [6]. - The ESOP holders are independent from the company's major shareholders and management, with a governance structure that prevents any single holder from exerting significant influence [6].
广东嘉应制药股份有限公司关于员工持股计划非交易过户完成的公告